Cinacalcet Tablet
NDC Package 43598-367-05
Package Information
Cinacalcet tablets is cinacalcet treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see Warnings and Precautions (5.1)]. This formulation utilizes a tablet delivery system. Marketed by Dr. Reddys Laboratories Inc, this product is identified by NDC 43598-367 and is authorized under FDA application ANDA208368.
Identification & Billing
- RxCUI: 432400 - cinacalcet HCl 90 MG Oral Tablet
- RxCUI: 432400 - cinacalcet 90 MG Oral Tablet
- RxCUI: 432400 - cinacalcet 90 MG (as cinacalcet HCl 99 MG) Oral Tablet
- RxCUI: 432401 - cinacalcet HCl 60 MG Oral Tablet
- RxCUI: 432401 - cinacalcet 60 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43598 - Dr. Reddys Laboratories Inc
- 43598-367 - Cinacalcet
- 43598-367-05 - 500 TABLET in 1 BOTTLE
- 43598-367 - Cinacalcet
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (43598-367). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43598-367-05 identifies a specific commercial package of 500 tablet in 1 bottle of Cinacalcet, a human prescription drug labeled by Dr. Reddys Laboratories Inc. This tablet is formulated for oral use and contains cinacalcet hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dr. Reddys Laboratories Inc on September 18, 2020.
How is this Dr. Reddys Laboratories Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43598036705. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.